Dr. Bisiayo Fashemi, a Post-doc Research Associate in the Khabele Lab, recently received a Diversity Supplement award from the National Cancer Institute of the National Institutes of Health (NIH). Through Dr. Khabele’s NIH R01-funded project titled, “Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer,” this supplement will bolster research in the area of novel combination therapeutic strategies and the identification of surrogate biomarkers to assess treatment efficiency in ovarian cancer. The Diversity Supplement awarded totals $69,487 from now til 2/28/23.
Congratulations Dr. Fashemi!